Stockscreener 앱 받기
26.78
0.81%
-0.22
시간 외 거래:
26.78
전일 마감가:
$27.00
열려 있는:
$27.06
하루 거래량:
210.95K
Relative Volume:
0.53
시가총액:
$1.23B
수익:
$722.68M
순이익/손실:
$134.71M
주가수익비율:
10.03
EPS:
2.67
순현금흐름:
$109.94M
1주 성능:
-0.11%
1개월 성능:
-3.32%
6개월 성능:
+16.64%
1년 성능:
-27.88%
1일 변동 폭
$26.64
$27.06
1주일 범위
$26.55
$27.23
52주 변동 폭
$20.39
$39.01
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
명칭
Amphastar Pharmaceuticals Inc
전화
909-980-9484
주소
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
AMPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
26.78 | 1.24B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-08-12 | 업그레이드 | Needham | Hold → Buy |
| 2025-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | 개시 | Wells Fargo | Equal Weight |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2023-11-17 | 개시 | BofA Securities | Neutral |
| 2023-07-25 | 재개 | Jefferies | Buy |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-07-29 | 개시 | CapitalOne | Overweight |
| 2022-01-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | 개시 | Northland Capital | Outperform |
| 2019-03-13 | 다운그레이드 | Needham | Buy → Hold |
| 2019-03-13 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-03-13 | 재확인 | Needham | Buy |
| 2017-12-01 | 재확인 | Needham | Buy |
| 2017-11-09 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | 재확인 | Needham | Buy |
| 2017-03-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-05-10 | 재확인 | Needham | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2015-06-19 | 재확인 | Needham | Buy |
| 2015-06-03 | 개시 | Raymond James | Strong Buy |
| 2014-07-21 | 개시 | Needham | Buy |
모두보기
Amphastar Pharmaceuticals Inc 주식(AMPH)의 최신 뉴스
Amphastar Pharmaceuticals Inc Stock Analysis and ForecastVolatility Index Analysis & Swing Trade Smarter With Data Insights - earlytimes.in
Will Amphastar Pharmaceuticals Inc. stock split again soonStock Screening Results & Make Confident Moves With Forecasting Models - bollywoodhelpline.com
Is Amphastar Pharmaceuticals Inc stock affected by interest rate hikesShort Setup & Reliable Intraday Trade Alerts - moha.gov.vn
How supply chain issues affect Amphastar Pharmaceuticals Inc. stockInstitutional Holding Changes & Minimal Investment Portfolio - bollywoodhelpline.com
Responsive Playbooks and the AMPH Inflection - Stock Traders Daily
Amphastar Director Sells 16,679 Shares for $441,800 - AOL.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC - MarketBeat
Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Teriparatide Pen Approval And Insider Stock Sale - Sahm
Amphastar Pharmaceuticals’ Resilient Q3 2025 Earnings Call - MSN
A Fresh Look at Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Stabilisation - Sahm
Will Amphastar Pharmaceuticals Inc. stock outperform international peersJuly 2025 Review & Community Trade Idea Sharing Platform - Улправда
Can Amphastar’s Recent Rebound Signal a Compelling Opportunity in 2025? - Sahm
Is Amphastar Pharmaceuticals Inc. (29A) stock dividend growth reliable2025 AllTime Highs & High Conviction Buy Zone Alerts - Улправда
Why Amphastar Pharmaceuticals Inc. (29A) stock could be top winnerJuly 2025 Price Swings & Weekly Stock Breakout Alerts - Улправда
Why retail investors favor Amphastar Pharmaceuticals Inc. stockTreasury Yields & Daily Entry Point Trade Alerts - Улправда
How strong is Amphastar Pharmaceuticals Inc. stock revenue growthEarnings Performance Report & Free Verified High Yield Trade Plans - Улправда
Is Amphastar Pharmaceuticals Inc. stock a smart buy before Fed meetingQuarterly Portfolio Review & Weekly Watchlist of Top Performers - DonanımHaber
Will Amphastar Pharmaceuticals Inc. stock benefit from AI adoption2025 Key Lessons & Real-Time Volume Spike Alerts - DonanımHaber
Is Amphastar Pharmaceuticals Inc. stock a buy for dividend growthJuly 2025 Chart Watch & AI Based Buy/Sell Signal Reports - DonanımHaber
Geopolitics Watch: Will Amphastar Pharmaceuticals Inc. stock outperform international peersJuly 2025 Closing Moves & Weekly Market Pulse Updates - Улправда
Growth Review: Is Amphastar Pharmaceuticals Inc. (29A) stock dividend growth reliable2025 Volatility Report & Weekly Watchlist for Consistent Profits - Улправда
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells 9,787 Shares of Stock - MarketBeat
Risk Analysis: Why retail investors favor Amphastar Pharmaceuticals Inc. stockTrade Exit Report & Reliable Breakout Forecasts - Улправда
Will Amphastar Pharmaceuticals Inc. (29A) stock beat value stocksJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - Улправда
Amphastar Pharmaceuticals Insider Sold Shares Worth $256,379, According to a Recent SEC Filing - marketscreener.com
Amphastar Pharmaceuticals Senior EVP Zhou Rong Sells Shares - TradingView — Track All Markets
Amphastar Pharmaceuticals (AMPH) executive logs option exercise and 9,787-share sale - Stock Titan
Rate Cut: Can Amphastar Pharmaceuticals Inc. stock withstand economic slowdownMarket Performance Summary & Stepwise Swing Trade Plans - Улправда
Amphastar reports FDA approval for teriparatide injection - MSN
Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative? - Yahoo Finance
Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile (NASDAQ:AMPH) - Seeking Alpha
Is FDA‑Cleared U.S.‑Made Teriparatide Pen Altering The Investment Case For Amphastar Pharmaceuticals (AMPH)? - simplywall.st
Amphastar Pharmaceuticals Director Makes Noteworthy Stock Sale - TipRanks
Insider Selling: Floyd Petersen Sells Shares of Amphastar Pharma - GuruFocus
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $44,623.53 in Stock - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $62,881.92 in Stock - MarketBeat
Amphastar Pharmaceuticals Director Sells Over 4,000 Shares - TradingView — Track All Markets
Dir Petersen Sells 4,163 ($107.5K) Of Amphastar Pharmaceuticals Inc [AMPH] - TradingView — Track All Markets
Amphastar Pharmaceuticals (AMPH) director discloses recent common stock sales - Stock Titan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 4.8%Still a Buy? - MarketBeat
Amphastar stock rises after FDA approval of teriparatide injection - Investing.com
Amphastar announces FDA approval for teriparatide injection - marketscreener.com
Amphastar Announces FDA Approval for Teriparatide Injection - ACCESS Newswire
What analysts say about Amphastar Pharmaceuticals Inc 29A stockTechnical Pattern Recognition & Access Free Tools and Start Investing - earlytimes.in
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Its Recent Share Price Slide - Sahm
Dir Petersen Files To Sell 4,163 Of Amphastar Pharmaceuticals Inc [AMPH] - TradingView — Track All Markets
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to "Hold" at Barclays - MarketBeat
Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025? - Sahm
Barclays Initiates Coverage of Amphastar Pharmaceuticals (AMPH) with Equal-Weight Recommendation - Nasdaq
Amphastar Pharmaceuticals Inc (AMPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.30%
0.62%
자본화:
|
볼륨(24시간):